Home › Funds › VOLORIDGE INVESTMENT MANAGEMENT, LLC › REGN
VOLORIDGE INVESTMENT MANAGEMENT, LLC position in REGN
REGENERON PHARMACEUTICALS · Health Care
VOLORIDGE INVESTMENT MANAGEMENT, LLC reported holding 163,963 shares of REGN (REGENERON PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$102.2M, representing 0.43% of its reported portfolio and ranking #46 among its reported holdings. VOLORIDGE INVESTMENT MANAGEMENT, LLC has disclosed REGN holdings in 8 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How VOLORIDGE INVESTMENT MANAGEMENT, LLC's REGN position evolved
VOLORIDGE INVESTMENT MANAGEMENT, LLC first disclosed a stake in REGN in Q3 2023 at 32,609 shares (US$26.8M). The position peaked in Q4 2024 at 212,128 shares, worth US$151.1M. Across 8 filings, VOLORIDGE INVESTMENT MANAGEMENT, LLC increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 163,963 shares valued at US$102.2M — an increase of 148,599 shares quarter over quarter.. Notable position changes include a 38% trim in Q3 2025 (shares rose 36% over the following quarter), a 967% increase in Q2 2026 (shares rose 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 32.61K | $26.84M | New |
| Q4 2023 | 33.21K | $29.17M | Add |
| Q4 2024 | 212.13K | $151.11M | New |
| Q1 2025 | 228.27K | $144.78M | Add |
| Q2 2025 | 279.86K | $146.93M | Add |
| Q3 2025 | 172.84K | $97.18M | Reduce |
| Q1 2026 | 15.36K | $11.87M | New |
| Q2 2026 | 163.96K | $102.24M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- LOOMIS SAYLES & CO L P 1.86M sh · $1.16B · Q2 2026
More on VOLORIDGE INVESTMENT MANAGEMENT, LLC
FAQ
How long has VOLORIDGE INVESTMENT MANAGEMENT, LLC held REGN?
VOLORIDGE INVESTMENT MANAGEMENT, LLC has disclosed REGN holdings in 8 of the last 12 reported quarters, going back to Q3 2023.
What is VOLORIDGE INVESTMENT MANAGEMENT, LLC's current position in REGN?
As of Q2 2026, VOLORIDGE INVESTMENT MANAGEMENT, LLC holds 163.96K shares of REGN (REGENERON PHARMACEUTICALS), valued at $102.24M, representing 0.43% of its reported portfolio and ranking #46.
Has VOLORIDGE INVESTMENT MANAGEMENT, LLC been buying or selling REGN?
In the latest 13F filing (Q2 2026), VOLORIDGE INVESTMENT MANAGEMENT, LLC increased its position in REGN. The position peaked in Q4 2024 at 212.13K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.